You are here: Home: CCU 3 | 2003: A CME Audio Series and Activity

Colorectal Cancer Update: A CME Audio Series and Activity

STATEMENT OF NEED/TARGET AUDIENCE

Colorectal cancer is among the most common cancers in the United States, and the arena of colorectal cancer treatment continues to evolve. Published results from ongoing clinical trials lead to the emergence of new therapeutic agents and regimens and changes in indications, doses and schedules for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well-informed of these advances. To bridge the gap between research and patient care, Colorectal Cancer Update utilizes one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME activity assists medical oncologists in the formulation of up-to-date clinical management strategies.

GLOBAL LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Describe ongoing clinical trials in colorectal cancer and their potential impact on patient care.
• Critically evaluate the clinical implications of emerging clinical trial data in colorectal cancer treatment.
• Develop and explain a management strategy for patients with colorectal cancer in the adjuvant and metastatic settings.

SPECIFIC LEARNING OBJECTIVES FOR ISSUE 3

Upon completion of this activity, participants should be able to:

• Counsel patients with metastatic colorectal cancer about the use of oxaliplatin- or irinotecan-containing chemotherapy regimens.
• Discuss the advantages of neoadjuvant chemotherapy in patients with colorectal cancer who have resectable liver metastases.
• Evaluate the potential future role for bevacizumab in the treatment of colorectal cancer in the metastatic and adjuvant setting.
• Describe the rationale and design of the planned NSABP trial of preoperative capecitabine for primary rectal cancer.
• Describe the planned NSABP-C-09 trial in order to counsel patients about eligibility for participation.
• Consider the implications of the MOSAIC trial for incorporation of oxaliplatin-containing regimens as adjuvant therapy for colorectal cancer.

ACCREDITATION STATEMENT

NL Communications Inc is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

NL Communications Inc designates this educational activity for a maximum of 2.75 category 1 credits towards the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent on the activity.